Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on August 6, 2018, reporting events occurring between June 25, 2018, and August 7, 2018. The filing details unregistered sales of equity securities and related debt transactions.
Key Financial Metrics and Transactions
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins). Instead, it reports specific capital raising and debt restructuring activities:
- Convertible Notes Issued: $100,000 principal amount issued between June 25 and July 2, 2018.
- Stock for Debt/Note Issuance: 5,000 shares issued for a $70,000 note; 10,000 shares issued for a maturity extension on a $250,000 note.
- Debt-for-Equity Swap: 395,055 shares issued to settle $406,799 of outstanding indebtedness (including accrued interest).
- Equity Financing: 60,000 shares and warrants for 60,000 shares issued for $150,000 in gross proceeds.
- Warrant Issuance: 35,000 shares warrant issued to a consultant for agreement extension.
Material Changes
The primary material change is a significant increase in outstanding common stock and warrant count due to the conversion of debt and new equity issuances. The company reduced its cash debt burden by approximately $406,799 through equity issuance. No prior period comparative financial data is provided in this specific filing.
Outlook, Risks, and Unusual Items
Management Commentary: The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for these transactions, asserting no public offering occurred and that investors were accredited with access to company information.
Unusual Items: The filing highlights a heavy reliance on issuing equity to service debt obligations and extend note maturities, indicating potential liquidity constraints.
Risks: Dilution of existing shareholders is a direct result of the 470,055 shares issued (excluding warrants) and the associated warrant grants.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the remaining cash debt obligations after the $406,799 debt-for-equity swap.
- Review the terms of the $100,000 convertible notes, specifically the conversion price mechanics after the initial six-month period.
- Check subsequent filings for the company's cash runway given the reliance on equity issuance for debt service.